| Completed | A Study of ADVATE in People With Hemophilia A in India Hemophilia A | Phase 4 | 2022-01-14 |
| Completed | A Study to Assess the Tolerability, Safety, and Pharmacokinetics of Subcutaneous Immune Globulin Infusion 10% Healthy Volunteers | Phase 1 | 2020-10-27 |
| Completed | A Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) in Japanese Participants With Primar Primary Immunodeficiency Diseases (PID) | Phase 3 | 2020-08-11 |
| Active Not Recruiting | A Long-term Study of ADYNOVI/ADYNOVATE in Participants With Haemophilia A Hemophilia A | — | 2020-07-09 |
| Terminated | A Phase 1/2 Study of SHP648, an Adeno-Associated Viral Vector for Gene Transfer in Hemophilia B Subjects Hemophilia B | Phase 1 / Phase 2 | 2020-05-13 |
| Completed | A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willeb Von Willebrand Disease (VWD) | Phase 3 | 2019-04-01 |
| Completed | FEIBA Reconstitution Volume Reduction and Faster Infusion Study (FEIBA STAR) Hemophilia A or B With Inhibitors | Phase 3 | 2019-02-12 |
| Completed | RIXUBIS PMS India (RIXUBIS PMS) Hemophilia B | Phase 4 | 2018-12-07 |
| Completed | Real-world CANadian CUvitru Non-Interventional Study in Subjects Transitioning From Subcutaneous Immunoglobuli Primary Immunodeficiency Diseases (PID) | — | 2018-09-24 |
| Completed | Prospective Psychometric Evaluation Study of a Patient-reported Outcomes (PRO) Instrument for Congenital Throm Congenital Thrombotic Thrombocytopenic Purpura | — | 2018-07-12 |
| Completed | A Study of BAX 888 in Male Adults With Severe Hemophilia A Hemophilia A | Phase 1 / Phase 2 | 2018-02-27 |
| Recruiting | A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebr Von Willebrand Disease | Phase 3 | 2017-11-06 |
| Completed | A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP) Thrombotic Thrombocytopenic Purpura (TTP) | Phase 3 | 2017-10-13 |
| Completed | Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subj Primary Immunodeficiency Diseases (PID) | Phase 3 | 2017-09-25 |
| Completed | Global Epidemiologic Study of Preexisting Immunity to AAV in Adults With Severe Hemophilia Hemophilia A, Hemophilia B | — | 2017-06-14 |
| Completed | Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD Subjects Primary Immunodeficiency Diseases (PID) | Phase 4 | 2017-05-30 |
| Terminated | A Phase 2/3 Study of GLASSIA for the Treatment of Acute GvHD Graft Versus Host Disease | Phase 2 / Phase 3 | 2017-04-26 |
| Completed | Non-Interventional Study to Capture the Patient Experience on Gene Therapy for Hemophilia Within the AskBio009 Hemophilia B | — | 2017-03-31 |
| Completed | Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia Hemophilia B | — | 2017-01-06 |
| Terminated | BAX 802 in CHA With Inhibitors Hemophilia A | Phase 3 | 2016-12-22 |
| Completed | Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Acquired Hemophilia A | — | 2016-12-14 |
| Completed | RIXUBIS Drug Use-Result Survey (Japan) Hemophilia B | — | 2016-11-16 |
| Completed | Long-Term Tolerability and Safety of HYQVIA/HyQvia in CIDP Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | 2016-11-14 |
| Terminated | Stage 1 Study of ARALAST NP and GLASSIA in A1PI Deficiency Chronic Obstructive Pulmonary Disease, Alpha1-antitrypsin Deficiency | Phase 3 | 2016-11-02 |
| Completed | GAS-Hem Feasibility Study Hemophilia A | — | 2016-08-05 |
| Completed | GLASSIA Safety, Immunogenicity, and Bronchoalveolar Lavage Study Alpha1-antitrypsin Deficiency | Phase 3 | 2016-03-08 |
| Completed | BAX 826 Dose-Escalation Safety Study Hemophilia A | Phase 1 | 2016-03-03 |
| Withdrawn | Efficacy and Safety of SM101 in the Treatment of IgA Nephropathy Immunoglobulin A Nephropathy | Phase 2 | 2015-12-31 |
| Completed | Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patien Acquired Hemophilia A | — | 2015-12-30 |
| Completed | Retrospective Chart Review to Evaluate Safety and Tolerability of ADVATE Among Previously Untreated Patients i Hemophilia A | — | 2015-12-23 |
| Completed | A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculo Chronic Inflammatory Demyelinating Polyradiculoneuropathy | Phase 3 | 2015-12-15 |
| Completed | Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia Exposure During Pregnancy | — | 2015-12-04 |
| Withdrawn | A Phase II Non-Controlled, Open-Label, Efficacy, Safety, Pharmacokinetic, and Pharmacodynamic Study of Pacriti Primary Myelofibrosis | Phase 2 | 2015-11-30 |
| Completed | BAX 855 PK-guided Dosing Hemophilia A | Phase 3 | 2015-11-23 |
| Completed | A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemop Hemophilia A | Phase 3 | 2015-11-12 |
| Completed | Non-Interventional Post-Marketing Safety Study on the Long-Term Safety of HYQVIA (Global) Primary Immunodeficiency Diseases (PID) | — | 2015-11-12 |
| Terminated | Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer Refractory Ovarian Cancer With Recurrent Symptomatic Malignant Ascites | Phase 1 / Phase 2 | 2015-11-02 |
| Terminated | Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Metastatic Colorectal Cancer | Phase 2 | 2015-06-15 |
| Completed | Recombinant Von Willebrand Factor in Subjects With Severe Von Willebrand Disease Undergoing Surgery Von Willebrand Disease | Phase 3 | 2015-04-01 |
| Completed | BAX 855 Pediatric Study Hemophilia A | Phase 3 | 2014-10-31 |
| Completed | Phase 1 Dose Escalation, Single Dose Study to Assess Safety and Pharmacokinetics of BAX930 in Hereditary Throm Hereditary Thrombotic Thrombocytopenic Purpura (TTP) | Phase 1 | 2014-09-30 |
| Completed | Study of Prophylaxis, ACtivity and Effectiveness (SPACE) in Hemophilia Patients Currently Treated With ADVATE Hemophilia A, Hemophilia B | — | 2014-07-22 |
| Completed | China ADVATE PTP Study Hemophilia A | Phase 4 | 2014-06-26 |
| Completed | Phase 3 Efficacy and Safety Study of BAX 855 in Severe Hemophilia A Patients Undergoing Surgical Procedures Hemophilia A | Phase 3 | 2013-12-20 |
| Terminated | Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease Sickle Cell Disease | Phase 2 | 2013-12-03 |
| Completed | BAX 855 Continuation Hemophilia A | Phase 3 | 2013-10-15 |
| Completed | ADVATE 2 mL Post-Authorization Safety Surveillance (PASS) Hemophilia A, Congenital Factor VIII (FVIII) Deficiency | — | 2013-09-20 |
| Completed | Recombinant Factor VIIa BI (rFVIIa BI) Treatment of Acute Bleeding Episodes Per an On-demand Regimen Hemophilia A, Hemophilia B | Phase 3 | 2013-02-20 |
| Active Not Recruiting | Open-Label Single Ascending Dose of Adeno-associated Virus Serotype 8 Factor IX Gene Therapy in Adults With He Hemophilia B | Phase 1 / Phase 2 | 2013-02-11 |
| Completed | Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study) Hemophilia A | Phase 2 / Phase 3 | 2013-01-31 |
| Completed | Phase 2/3 Study of IGSC, 20% in PIDD Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | 2013-01-28 |
| Terminated | Long-Term Study of IGIV, 10% in Alzheimer´s Disease Alzheimer´s Disease | Phase 3 | 2012-11-29 |
| Completed | GLASSIA Infusion Rate Study Alpha1-antitrypsin Deficiency, Healthy Volunteers | Phase 4 | 2012-07-31 |
| Completed | Phase 1 Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Solid Tumors Metastatic Adenocarcinoma of the Colon or Rectum, Malignant Solid Tumors | Phase 1 | 2012-06-14 |
| Completed | A Single Dose Study of the Safety, Blood Levels and Biological Effects of Aes-103 Compared to Placebo in Subje Sickle Cell Disease | Phase 1 | 2012-05-12 |
| Terminated | Phase 3 IGIV, 10% in Alzheimer´s Disease Alzheimer´s Disease | Phase 3 | 2012-01-23 |
| Completed | Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | 2011-12-29 |
| Completed | BAX 326 Pediatric Study Hemophilia B | Phase 2 / Phase 3 | 2011-12-20 |
| Completed | BAX 326 Surgery Study in Hemophilia B Patients Hemophilia B | Phase 3 | 2011-12-19 |
| Terminated | Safety Study of Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody in Lupus Nephritis Systemic Lupus Erythematosus | Phase 1 | 2011-11-28 |
| Completed | Pharmacokinetics, Safety and Efficacy of Recombinant Von Willebrand Factor (rVWF) in the Treatment of Bleeding Von Willebrand Disease | Phase 3 | 2011-11-01 |
| Terminated | Osteoporosis and MRI Study in Hemophilia Bone Mineral Density, Hemophilia A, Hemophilia B | N/A | 2011-10-30 |
| Terminated | Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Congenital Hemophilia A Hemophilia A | Phase 3 | 2011-10-03 |
| Completed | BAX 855 Dose-Escalation Safety Study Hemophilia A | Phase 1 | 2011-09-30 |
| Terminated | Early Prophylaxis Immunologic Challenge (EPIC) Study Hemophilia A | Phase 3 | 2011-08-26 |
| Completed | ADVATE/ ADYNOVI Hemophilia A Outcome Database (AHEAD) Hemophilia A | — | 2011-06-28 |
| Completed | Immune Globulin Subcutaenous (Human), 20% Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | 2011-06-20 |
| Completed | BAX 326 (rFIX) Continuation Study Hemophilia B | Phase 3 | 2011-04-12 |
| Completed | Phase 1/2 Lyme Vaccine Study Prophylaxis of Lyme Borreliosis | Phase 1 / Phase 2 | 2011-03-01 |
| Completed | Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A Acquired Hemophilia A | Phase 2 / Phase 3 | 2010-11-10 |
| Terminated | First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients Hemophilia | Phase 1 | 2010-09-15 |
| Completed | Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients Hemophilia B | Phase 3 | 2010-07-29 |
| Completed | Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID Primary Immunodeficiency Diseases (PID) | Phase 3 | 2010-07-28 |
| Completed | Efficacy and Safety of Prothromplex Total (Prothrombin Complex Concentrate) in Oral Anticoagulant Reversal Prothrombin Complex Factor Deficiency | Phase 4 | 2010-07-09 |
| Completed | Ceprotin Treatment Registry Protein C Deficiency | — | 2010-06-23 |
| Completed | IMMUNINE Pre-Treatment Study Hemophilia B | Phase 4 | 2010-05-31 |
| Completed | Phase 1 Dosing Study of BAX 513 in Healthy Volunteers Healthy Volunteers | Phase 1 | 2010-01-29 |
| Completed | Pharmacokinetic Study of ADVATE 3000 IU in Previously Treated Patients With Severe Hemophilia A Hemophilia A | Phase 4 | 2009-06-29 |
| Completed | Efficacy and Safety Study of Prophylactic Versus On-Demand Treatment With Feiba NF in Subjects With Hemophilia Hemophilia A or B With Inhibitors, Hemophilia A, Hemophilia B | Phase 3 | 2009-03-31 |
| Completed | A Phase 3 Study Evaluating Safety and Effectiveness of Immune Globulin Intravenous (IGIV 10%) for the Treatmen Alzheimer´s Disease | Phase 3 | 2008-12-19 |
| Completed | Gammagard Liquid and rHuPH20 in PID Primary Immunodeficiency Diseases (PID) | Phase 3 | 2008-12-18 |
| Completed | Pharmacokinetic, Safety and Tolerability Study of Recombinant Von Willebrand Factor / Recombinant Factor VIII Von Willebrand Disease | Phase 1 | 2008-12-01 |
| Completed | Study of the Effectiveness of Intravenous Immune Globulin (10%) for the Treatment of Multifocal Motor Neuropat Multifocal Motor Neuropathy | Phase 3 | 2008-08-22 |
| Completed | Pharmacokinetic Study of ADVATE Reconstituted in 2 mL Sterile Water for Injection Hemophilia A | Phase 1 | 2008-08-08 |
| Completed | Pharmacokinetic Comparison of Advate rAHF-PFM With Recombinate rAHF in Patients With Severe Hemophilia A Hemophilia A | Phase 4 | 2008-03-31 |
| Completed | A Study of Plasma-Derived Human Butyrylcholinesterase Administered Intramuscularly Healthy Volunteers | Phase 1 | 2007-12-01 |
| Completed | Comparison of Intravenous and Subcutaneous Administration of IGIV, 10% in Primary Immunodeficiency (PID) Subje Primary Immunodeficiency Diseases (PID) | Phase 2 / Phase 3 | 2007-10-03 |
| Completed | Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously Healthy Volunteers, Chemical Terrorism, Chemical Warfare | Phase 1 | 2007-01-01 |
| Completed | Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneo Primary Immunodeficiency Diseases (PID) | Phase 1 / Phase 2 | 2006-12-04 |
| Completed | Efficacy and Safety Study of Augmentation Therapy With ARALAST Fraction IV-1 (Human Alpha 1 - Proteinase Inhib Alpha 1-Antitrypsin Deficiency | Phase 4 | 2006-10-27 |
| Terminated | Aralast alpha1-proteinase Inhibitor Surveillance Study Alpha1-antitrypsin Deficiency | Phase 4 | 2006-06-09 |
| Completed | Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Hemophilia A | Phase 4 | 2006-05-29 |
| Completed | Dose-Response Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophili Hemophilia A | Phase 4 | 2006-02-02 |
| Completed | Prophylaxis Study of Recombinant Factor VIII Manufactured Protein-Free (rAHF-PFM) in Patients With Hemophilia Hemophilia A | Phase 4 | 2006-01-04 |
| Completed | Pharmacokinetic Study of ARALAST (Human Alpha1- PI) Alpha 1-Antitrypsin Deficiency | Phase 1 | 2005-12-20 |
| Completed | Retrospective Study to Capture Dosing and Treatment Outcome Data in Participants With Severe Congenital Protei Protein C Deficiency | — | 2005-06-01 |
| Completed | Efficacy and Safety Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pediatric Patients in Ca Hemophilia A | Phase 2 / Phase 3 | 2004-12-17 |
| Completed | ADVATE Post Authorization Safety Surveillance Hemophilia A | — | 2004-10-14 |
| Completed | Efficacy and Safety Study of a Recombinant Protein-Free Manufactured Factor VIII (rAHF-PFM) in Previously Untr Hemophilia A | Phase 3 | 2004-04-01 |
| Completed | Study of the Effect of Aerosolized, Recombinant Alpha 1-Antitrypsin on Epithelial Lining Fluid Analytes in Sub Alpha1-antitrypsin Deficiency | Phase 1 / Phase 2 | 2004-03-01 |
| Completed | Efficacy and Safety Study of Protein C Concentrate in Subjects With Severe Congenital Protein C Deficiency Protein C Deficiency | Phase 2 / Phase 3 | 2003-08-22 |
| Completed | Pharmacokinetics, Efficacy and Safety Study of IMMUNATE SD (Human Plasma-Derived Coagulation Factor VIII Conce Hemophilia A | Phase 3 | 2003-03-31 |
| Completed | Efficacy and Safety Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solution in Adult Subjec Immune Thrombocytopenic Purpura (ITP) | Phase 2 | 2003-01-13 |
| Completed | Safety Study of an Aerosolized, Recombinant Alpha 1-Antitrypsin in Subjects With Alpha 1-Antitrypsin Deficienc Alpha1-antitrypsin Deficiency | Phase 1 / Phase 2 | 2003-01-07 |
| Completed | Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficie Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP), Kawasaki Syndrome | Phase 3 | 2002-06-25 |
| Completed | Safety, Pharmacokinetic and Efficacy Study of a 10% Triple Virally Reduced Intravenous Immune Globulin Solutio Primary Immunodeficiency Diseases (PID), Agammaglobulinemia, Hypogammaglobulinemia | Phase 2 | 2002-06-13 |
| Completed | Study of Pharmacokinetics, Efficacy, and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Pe Hemophilia A | Phase 2 / Phase 3 | 2002-06-07 |
| Completed | Study of Pharmacokinetics, Efficacy and Safety of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hem Hemophilia A | Phase 2 / Phase 3 | 2001-11-22 |
| Completed | Safety and Efficacy Study of a Recombinant and Protein-Free Factor VIII (rAHF-PFM) in Hemophilia A Patients Un Hemophilia A | Phase 2 / Phase 3 | 2001-02-12 |
| Terminated | Prevention of Graft-Versus-Host Disease in Patients With Advanced Leukemia or Lymphoma Who Are Eligible for Pe Leukemia, Lymphoma, Graft Versus Host Disease | Phase 3 | 1997-04-01 |
| No Longer Available | Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemop Acquired Hemophilia A | — | — |